Clinical trials: Pioglitazone
Heroin Dependence, Nicotine Dependence
Pioglitazone for Heroin and for Nicotine Dependence
The goal of the proposed research is to improve the effectiveness of treatments for opioid and for nicotine dependence by testing a novel pharmacological strategy.
- Trial name
- NCT01395797
- Testing
- PIO
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Severe Sepsis, Septic Shock
Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock
The purpose of this study is to evaluate the pharmacokinetics of pioglitazone and to determine the effect on inflammatory biomarkers for pioglitazone in patients with severe sepsis and septic shock.
- Trial name
- NCT01352182
- Testing
- Pioglitazone hydrochloride
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Type 2 Diabetes
Effect of Pioglitazone Therapy for Type 2 Diabetes on Vision
We are studying patients with diabetes who under proper medical care and administer an approved drug. Our interest is if this drug has any sideeffect on vision and if this drug may cause swelling of the retina.
- Trial name
- NCT00548158
- Volunteers
- 19 people
- Sponsor
- University of California, San Diego
Opioid Abuse
Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone
The ability of pioglitazone (PIO) to alter the effects of opioids in humans has not been characterized in a controlled laboratory setting.
- Trial name
- NCT01395784
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
PCOS
Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome
The investigators aim is to conduct a double blind randomized clinical trial, to study the effects of combined Resveratrol and Myo-Inositol on altered metabolic, endocrine parameters and perceived stress response in patients with…
- Trial name
- NCT04867252
- Testing
- Resveratrol (1000mg twice a day), Myoinositol 1000mg (Twice a day), Metformin (500 mg Twice a day), Pioglitazone (15 mg Twice a day)
- Where
- Pakistan
- Volunteers
- 88 people
- Sponsor
- Khyber Medical University Peshawar
Atherosclerosis, Cardiovascular Diseases
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
The purpose of this study is to prevent major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes mellitus using intensive glycemic control, intensive blood pressure control, and…
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension
- Trial name
- ACCORD (NCT00000620)
- Testing
- Anti-hyperglycemic Agents, Anti-hypertensive Agents
- Where
- 7 sites in United States, Canada
- Volunteers
- 10,251 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Type 2 Diabetes, Fatty Liver
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty…
- Trial name
- NCT06989723
- Testing
- Pioglitazone 15 MG [Actos], Empagliflozin 10 MG [Jardiance], Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Seoul National University Bundang Hospital
Diabetes Mellitus, Kidney Transplantation
Influence of Pioglitazone for Renal Transplant Function in Diabetics
The purpose of this study is to test whether pioglitazone is able to prevent the progression of diabetic nephropathy in kidney transplant recipients with diabetes mellitus.
- Conditions
- Diabetes Mellitus, Kidney Transplantation, Proteinuria
- Trial name
- NCT00507494
- Testing
- pioglitazone
- Where
- Germany
- Sponsor
- Technische Universität Dresden
Healthy
CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
This initial Phase I study will evaluate the dose-related safety and tolerability pharmacokinetics (PK) of CORT125281, and CORT125324 (active metabolite), and pharmacodynamics (PD) after single and multiple ascending oral doses…
- Trial name
- NCT03335956
- Testing
- CORT125281, 40mg, fasted, Prednisone 25mg, fasted, Pioglitazone 15mg Tablet
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Diabetes Mellitus, Type 2
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone
This study will evaluate the long-term safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- REDWOOD403 (NCT01089790)
- Testing
- Dutogliptin, Sitagliptin
- Where
- 149 sites in United States
- Volunteers
- 141 people
- Sponsor
- Forest Laboratories
Type 2 Diabetes Mellitus
Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects
The present study was undertaken to assess the efficacy and safety of two different insulin sensitizers (namely Pioglitazone and Metformin) among subjects with type 2 diabetes mellitus (T2DM) in Bangladesh.
- Trial name
- T2DMCT (NCT01589445)
- Testing
- Pioglitazone hydrochloride, Metformin hydrochloride
- Where
- Bangladesh
- Volunteers
- 77 people
- Sponsor
- University of Dhaka
Peritoneal Dialysis, Pioglitazone
Pioglitazone Attenuates Dysmetabolism in Peritoneal Dialysis (PD) Patients
1. Background:Cardiovascular disease (CVD) is the major cause of mortality in peritoneal dialysis (PD) patients, in whom it is partly attributable to a higher prevalence of dysmetabolism.
- Conditions
- Peritoneal Dialysis, Pioglitazone, Hypertriglyceridemia, Insulin Resistance
- Trial name
- NCT01258322
- Testing
- Pioglitazone
- Volunteers
- 70 people
- Sponsor
- Huashan Hospital
Uric Acid Kidney Stone Disease
Pathophysiology of Uric Acid Nephrolithiasis
This study has two aims: Aim 1: To determine the presence of accumulation of fat within cells and the functional consequences of this in the kidney by correlating kidney fat content with urine test results.
- Trial name
- IUAN (NCT00904046)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- University of Texas Southwestern Medical Center
Type 2 Diabetes Mellitus
Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes
The purpose of this study is to compare Muraglitazar and Pioglitazone in patients with Type 2 Diabetes. Both the safety and blood sugar lowering effects of these treatments will be studied.
- Trial name
- NCT00106808
- Testing
- Muraglitazar, Pioglitazone
- Where
- 195 sites in United States, Argentina and 12 more
- Volunteers
- 1,440 people
- Sponsor
- Bristol-Myers Squibb
Prediabetic State
DPP-4 Inhibition and TZD for DM Prevention
To determine whether treatment with the diabetes medication, Januvia (sitagliptin), with or without another diabetes medicine, Actos (pioglitazone), will improve insulin secretion and insulin response individuals with Impaired…
- Trial name
- DInT DM (NCT01006018)
- Testing
- Sitagliptin + Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Emory University
Chronic Kidney Diseases
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in…
- Trial name
- NCT03471117
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas at Arlington
Type 2 Diabetes Mellitus
A 2 Year Trial of Patients With Type 2 Diabetes Focusing on Cardiovascular Diagnostics and Metabolic Control
The purposes of this study are: to investigate the extent of cardiovascular complications in a representative cohort (n=135) of adult patients with type 2 diabetes; to examine if modern non-invasive assessment can replace…
- Trial name
- NCT00133718
- Testing
- Combined lifestyle intervention and optimisation of pharmacological treatment
- Where
- Norway
- Volunteers
- 120 people
- Sponsor
- Asker & Baerum Hospital
Risk Reduction
Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF
The prevalence of type 2 diabetes mellitus (T2DM) in Qatar and nations worldwide has increased in recent decades into epidemic proportions. Cardiovascular (CVD) disease is the leading cause of death in T2DM patients.
- Trial name
- NCT03794518
- Testing
- Pioglitazone Plus dapaglifliozin
- Where
- Qatar
- Volunteers
- 648 people
- Sponsor
- Hamad Medical Corporation
Healthy
Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers
The objective of the study was to investigate whether there is a drug-drug interaction between BI 10773 and pioglitazone when co-administered as multiple oral doses.
- Trial name
- NCT02276365
- Testing
- BI 10773, Pioglitazone
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322
To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.
- Trial name
- NCT01686711
- Testing
- AD-4833 15 mg, AD-4833 30 mg
- Where
- 25 sites in Japan
- Volunteers
- 207 people
- Sponsor
- Takeda